Drug Search Results
More Filters [+]

Ganciclovir

Alternative Names: ganciclovir, gancyclovir, cytovene, zirgan, gv-550, gv 550, gv550, ganzyk-rtu, vitrasert
Latest Update: 2024-08-28
Latest Update Note: Clinical Trial Update

Product Description

Ganciclovir capsules are used to treat cytomegalovirus (CMV) retinitis (eye infection that can cause blindness) in people whose immune system is not working normally. Ganciclovir capsules are used to treat CMV retinitis after the condition has been controlled by intravenous (injected into a vein) ganciclovir. Ganciclovir is also used to prevent cytomegalovirus (CMV) disease in people who have acquired immunodeficiency syndrome (AIDS) or who have received an organ transplant and are at risk of CMV disease. Ganciclovir is in a class of medications called antivirals. It works by preventing the spread of CMV disease or slowing the growth of CMV. (Sourced from: https://medlineplus.gov/druginfo/meds/a605011.html)

Mechanisms of Action: DNA Polymerase Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Retinitis | Acquired Immunodeficiency Syndrome | Keratitis | Keratitis, Dendritic | Keratitis, Herpetic | Retinitis | Cytomegalovirus Retinitis | Acquired Immunodeficiency Syndrome

Known Adverse Events: Anemia | Leukopenia | Sepsis | Diarrhea | Hyperemia | Keratitis | Pregnancy Outcomes | Keratitis, Herpetic | Abdominal Pain | Headache | Labor Pain | Pain Unspecified | Hyperhidrosis | Dyspnea | Asthenia

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ganciclovir

Countries in Clinic: Australia, China, Japan, Spain

Active Clinical Trial Count: 7

Highest Development Phases

Phase 3: Allogeneic Stem Cell Transplant|Communicable Diseases|Cytomegalovirus Infections|Hematopoietic Stem Cell Transplant|Liver Cancer|Liver Transplant|Lung Transplant

Phase 2: Herpes Simplex|Keratitis

Phase 1: Autism Spectrum Disorder

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BD-HSK-111002-Ⅱa

P2

Not yet recruiting

Herpes Simplex|Keratitis

2025-12-01

CYTOCOR

P3

Completed

Communicable Diseases|Cytomegalovirus Infections

2023-05-29

jRCT2051210064

P3

Active, not recruiting

Unknown

2022-12-31

CYTOCOR

P3

Active, not recruiting

Lung Transplant

2022-11-02

Recent News Events